• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    10 Health Care Stocks With Whale Alerts In Today's Session

    5/28/24 1:35:22 PM ET
    $BMY
    $CVS
    $DHR
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $BMY alert in real time by email

    This whale alert can help traders discover the next big trading opportunities.

    Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

    Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels.

    Below are some instances of options activity happening in the Health Care sector:

    Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
    GERN CALL TRADE BULLISH 09/20/24 $3.50 $350.0K 833 5.0K
    ZTS PUT SWEEP BULLISH 07/19/24 $165.00 $45.5K 289 791
    ITOS CALL SWEEP BEARISH 10/18/24 $25.00 $66.0K 2.0K 501
    BMY CALL TRADE BULLISH 01/16/26 $55.00 $63.9K 9.1K 461
    MRK CALL TRADE BEARISH 01/17/25 $145.00 $29.2K 1.7K 233
    CVS PUT SWEEP BEARISH 11/15/24 $52.50 $100.8K 769 227
    TMO CALL TRADE BEARISH 06/28/24 $590.00 $92.3K 1 170
    DHR CALL SWEEP BEARISH 01/17/25 $270.00 $60.6K 1.0K 146
    LLY CALL TRADE BEARISH 01/17/25 $760.00 $1.1 million 263 107
    WAT PUT TRADE BEARISH 06/21/24 $320.00 $43.0K 32 100

    Explanation

    These itemized elaborations have been created using the accompanying table.

    • Regarding GERN (NASDAQ:GERN), we observe a call option trade with bullish sentiment. It expires in 115 day(s) on September 20, 2024. Parties traded 5000 contract(s) at a $3.50 strike. The total cost received by the writing party (or parties) was $350.0K, with a price of $70.0 per contract. There were 833 open contracts at this strike prior to today, and today 5000 contract(s) were bought and sold.

    • Regarding ZTS (NYSE:ZTS), we observe a put option sweep with bullish sentiment. It expires in 52 day(s) on July 19, 2024. Parties traded 138 contract(s) at a $165.00 strike. This particular put needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $45.5K, with a price of $330.0 per contract. There were 289 open contracts at this strike prior to today, and today 791 contract(s) were bought and sold.

    • Regarding ITOS (NASDAQ:ITOS), we observe a call option sweep with bearish sentiment. It expires in 143 day(s) on October 18, 2024. Parties traded 330 contract(s) at a $25.00 strike. This particular call needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $66.0K, with a price of $200.0 per contract. There were 2000 open contracts at this strike prior to today, and today 501 contract(s) were bought and sold.

    • Regarding BMY (NYSE:BMY), we observe a call option trade with bullish sentiment. It expires in 598 day(s) on January 16, 2026. Parties traded 385 contract(s) at a $55.00 strike. The total cost received by the writing party (or parties) was $63.9K, with a price of $166.0 per contract. There were 9174 open contracts at this strike prior to today, and today 461 contract(s) were bought and sold.

    • For MRK (NYSE:MRK), we notice a call option trade that happens to be bearish, expiring in 234 day(s) on January 17, 2025. This event was a transfer of 130 contract(s) at a $145.00 strike. The total cost received by the writing party (or parties) was $29.2K, with a price of $225.0 per contract. There were 1709 open contracts at this strike prior to today, and today 233 contract(s) were bought and sold.

    • Regarding CVS (NYSE:CVS), we observe a put option sweep with bearish sentiment. It expires in 171 day(s) on November 15, 2024. Parties traded 284 contract(s) at a $52.50 strike. This particular put needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $100.8K, with a price of $355.0 per contract. There were 769 open contracts at this strike prior to today, and today 227 contract(s) were bought and sold.

    • Regarding TMO (NYSE:TMO), we observe a call option trade with bearish sentiment. It expires in 31 day(s) on June 28, 2024. Parties traded 170 contract(s) at a $590.00 strike. The total cost received by the writing party (or parties) was $92.3K, with a price of $543.0 per contract. There were 1 open contracts at this strike prior to today, and today 170 contract(s) were bought and sold.

    • Regarding DHR (NYSE:DHR), we observe a call option sweep with bearish sentiment. It expires in 234 day(s) on January 17, 2025. Parties traded 37 contract(s) at a $270.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $60.6K, with a price of $1640.0 per contract. There were 1079 open contracts at this strike prior to today, and today 146 contract(s) were bought and sold.

    • Regarding LLY (NYSE:LLY), we observe a call option trade with bearish sentiment. It expires in 234 day(s) on January 17, 2025. Parties traded 100 contract(s) at a $760.00 strike. The total cost received by the writing party (or parties) was $1.1 million, with a price of $11510.0 per contract. There were 263 open contracts at this strike prior to today, and today 107 contract(s) were bought and sold.

    • For WAT (NYSE:WAT), we notice a put option trade that happens to be bearish, expiring in 24 day(s) on June 21, 2024. This event was a transfer of 100 contract(s) at a $320.00 strike. The total cost received by the writing party (or parties) was $43.0K, with a price of $430.0 per contract. There were 32 open contracts at this strike prior to today, and today 100 contract(s) were bought and sold.

    Options Alert Terminology
    - Call Contracts: The right to buy shares as indicated in the contract.
    - Put Contracts: The right to sell shares as indicated in the contract.
    - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it.
    - Premium/Option Price: The price of the contract.

    For more information, visit our Guide to Understanding Options Alerts or read more about unusual options activity.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BMY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BMY
    $CVS
    $DHR
    $GERN

    CompanyDatePrice TargetRatingAnalyst
    Merck & Company Inc.
    $MRK
    2/25/2026$142.00Outperform
    RBC Capital Mkts
    Eli Lilly and Company
    $LLY
    2/25/2026$1250.00Outperform
    RBC Capital Mkts
    Bristol-Myers Squibb Company
    $BMY
    2/25/2026$60.00Sector Perform
    RBC Capital Mkts
    Merck & Company Inc.
    $MRK
    2/20/2026$140.00Overweight
    Barclays
    Eli Lilly and Company
    $LLY
    2/20/2026$1350.00Overweight
    Barclays
    Bristol-Myers Squibb Company
    $BMY
    2/20/2026$75.00Overweight
    Barclays
    Merck & Company Inc.
    $MRK
    2/13/2026$150.00Hold → Buy
    Deutsche Bank
    Waters Corporation
    $WAT
    2/10/2026$360.00In-line
    Evercore ISI
    More analyst ratings

    $BMY
    $CVS
    $DHR
    $GERN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fearon Richard H bought $306,340 worth of shares (1,000 units at $306.34), increasing direct ownership by 43% to 3,302 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    3/10/26 4:21:34 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Norden Gregory gifted 1,213 shares, closing all direct ownership in the company (SEC Form 4)

    4 - Zoetis Inc. (0001555280) (Issuer)

    3/10/26 4:20:48 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Meyer James claimed ownership of 5,891 shares (SEC Form 3)

    3 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

    3/10/26 4:07:46 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $BMY
    $CVS
    $DHR
    $GERN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    September 26, 2024 - FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

    For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.   “Schizophrenia is a leading

    9/26/24 6:42:20 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 14, 2024 - FDA Roundup: June 14, 2024

    For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r

    6/14/24 3:54:45 PM ET
    $MMSI
    $BMY
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    June 7, 2024 - FDA Roundup: June 7, 2024

    For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu

    6/7/24 3:46:22 PM ET
    $GERN
    $SRAX
    $SNAP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Advertising
    Consumer Discretionary

    $BMY
    $CVS
    $DHR
    $GERN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CVS Health Foundation Invests $2.24 Million to Expand Community‑Based Care Through Health Impact Ohio

    Health Zones effort aims to improve health care access, reduce emergency utilization and support residents with chronic conditionsCOLUMBUS, Ohio, March 10, 2026 /PRNewswire/ --The CVS Health Foundation today announced the launch of its Health Zone in Columbus with a $2.24 million investment in Health Impact Ohio to help improve access to health care, reduce emergency care utilization and support residents with chronic and behavioral health conditions. "Families across the south and east sides of Columbus continue to face significant and interconnected challenges," said Jenny McC

    3/10/26 9:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Waters Flagship ARES‑G3 Rheometer Sets New Benchmark for Data Quality at Breakthrough Speed

    News Summary:Reduces standard testing times by 80%.1Delivers an industry-leading 25,000 data points per second, detecting transient material behaviors previously invisible to measurement. 2Operates with fewer calibrations and superior atmosphere and temperature control. 3SAN ANTONIO, Texas and MILFORD, Mass., March 9, 2026 /CNW/ -- Pittcon 2026 Conference + Exposition -- Waters Corporation (NYSE: WAT) today launched the ARES-G3™ Rheometer, part of the TA Instruments product line. This next-generation rheometer delivers industry-leading speed paired with best-in-class data to accelerate materials research and product development. Capturing up to 25,000 data points per second (10x more than it

    3/9/26 8:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma

    Study marks the first positive Phase 3 study for mezigdomide and the second positive Phase 3 study for the Bristol Myers Squibb CELMoD program Bristol Myers Squibb (NYSE:BMY) today announced positive interim Phase 3 results from the SUCCESSOR-2 study (NCT05552976). In the trial, oral mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus carfilzomib and dexamethasone alone (Kd) in patients with relapsed or refractory multiple myeloma (RRMM). Safety findings were consistent with the known profile of mezigdomide and the combination regimen. Patients will con

    3/9/26 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMY
    $CVS
    $DHR
    $GERN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fearon Richard H bought $306,340 worth of shares (1,000 units at $306.34), increasing direct ownership by 43% to 3,302 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    3/10/26 4:21:34 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EVP and President, Aetna Nelson Steven H bought $1,289 worth of shares (24 units at $53.70) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    1/27/26 5:20:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    EVP and Chief People Officer Capozzi Heidi B bought $4,589 worth of shares (80 units at $57.36) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    10/14/25 7:08:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $BMY
    $CVS
    $DHR
    $GERN
    SEC Filings

    View All

    SEC Form PRE 14A filed by Eli Lilly and Company

    PRE 14A - ELI LILLY & Co (0000059478) (Filer)

    3/6/26 4:35:56 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Thermo Fisher Scientific Inc

    144 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)

    3/3/26 12:23:47 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    SEC Form 144 filed by Thermo Fisher Scientific Inc

    144 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)

    3/3/26 10:43:12 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $BMY
    $CVS
    $DHR
    $GERN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on Merck with a new price target

    RBC Capital Mkts initiated coverage of Merck with a rating of Outperform and set a new price target of $142.00

    2/25/26 7:52:46 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on Eli Lilly with a new price target

    RBC Capital Mkts initiated coverage of Eli Lilly with a rating of Outperform and set a new price target of $1,250.00

    2/25/26 7:51:49 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on Bristol-Myers with a new price target

    RBC Capital Mkts initiated coverage of Bristol-Myers with a rating of Sector Perform and set a new price target of $60.00

    2/25/26 7:49:08 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMY
    $CVS
    $DHR
    $GERN
    Leadership Updates

    Live Leadership Updates

    View All

    Merck Evolves Human Health Operating Structure to Support Portfolio Execution

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today highlighted steps to evolve the structure of its Human Health organization to ensure strong commercial execution of launches across diverse therapeutic areas, positioning the company for continued commercial success. As part of this evolution, Merck is organizing its Human Health business into an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. This structure will enable Merck to sustain long-term leadership in oncology, while maintaining a sharp focus in support of a growing number of launches across an increasingly broad and diverse portfolio. In support of the new Human He

    2/23/26 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Danaher To Acquire Masimo Corporation

    WASHINGTON, Feb. 17, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ:MASI) a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care settings. Under the terms of the agreement, Danaher will acquire all of the outstanding shares of Masimo common stock for $180 per share in cash, or a total enterprise value of approximately $9.9 billion including assumed indebtedness and net of acquired cash. This represents a transaction multiple of approximately 18x estimated 2027 EBITDA, or 15x 2

    2/17/26 8:00:00 AM ET
    $DHR
    $MASI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Waters Completes Combination with BD's Biosciences & Diagnostic Solutions Businesses

    Announces appointment of Claire M. Fraser, Ph.D., to its Board of DirectorsForms a global life sciences and diagnostics leader focused on high-volume testing in regulated applicationsAnnounces formation of four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials SciencesMILFORD, Mass., Feb. 9, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) ("Waters") today announced it has completed the previously announced combination with the Biosciences & Diagnostic Solutions businesses of Becton, Dickinson and Company (NYSE:BDX) ("BD"). The transaction forms a global life sciences and diagnostics leader, equipped with best-in-class technologies

    2/9/26 8:40:00 AM ET
    $BDX
    $WAT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BMY
    $CVS
    $DHR
    $GERN
    Financials

    Live finance-specific insights

    View All

    NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET

    CALABASAS, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced data from the dose-escalation portion of its Phase 1/2 clinical trial for NEO212, the Company's novel oral bio-conjugated therapy and will host a conference call to discuss the data today at 9:00am ET. NeOnc has formally notified the FDA that the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial has reached Maximum Tolerated Dose (MTD) at Cohort 5 (810 mg, Days 1–5, 28-day cycle) following a second

    3/4/26 8:00:00 AM ET
    $MRK
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bristol Myers Squibb Announces Dividend

    Bristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the company. The dividend is payable on May 1, 2026, to stockholders of record at the close of business on April 2, 2026. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the future of medicine and the patients we serve. For more information about Bristol Myers Squibb, visit u

    3/2/26 4:16:00 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Thermo Fisher Scientific Increases Quarterly Dividend

    Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.47 per common share, payable on April 15, 2026, to shareholders of record as of March 13, 2026. This reflects a 10% increase over the previous dividend payment of $0.43. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in thei

    2/25/26 4:15:00 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $BMY
    $CVS
    $DHR
    $GERN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by iTeos Therapeutics Inc.

    SC 13G - iTeos Therapeutics, Inc. (0001808865) (Subject)

    11/21/24 8:27:38 PM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by iTeos Therapeutics Inc.

    SC 13D/A - iTeos Therapeutics, Inc. (0001808865) (Subject)

    11/19/24 9:57:32 AM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by iTeos Therapeutics Inc.

    SC 13D/A - iTeos Therapeutics, Inc. (0001808865) (Subject)

    11/18/24 9:57:13 PM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care